Free Access
J Extra Corpor Technol
Volume 39, Number 4, December 2007
Page(s) 308 - 310
Published online 15 December 2007
  1. Nalysnyk L, Fahrbach K, Reynolds MW, Zhao SZ, Ross S. Adverse events in coronary artery bypass graft (CABG) trials: A systematic review and analysis. Heart. 2003;89:767–72. [CrossRef] [Google Scholar]
  2. Despotis G, Filos KS, Zoys TN, Hogue CWJr, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients. Anesth Analg. 1996;82:13–21. [Google Scholar]
  3. Grayson AD, Jackson M, Desmond MJ. Monitoring blood transfusion in patients undergoing coronary artery bypass grafting: An audit methodology. Vox Sang. 2003;85:96–101. [CrossRef] [PubMed] [Google Scholar]
  4. Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anaesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83:S27–86. [CrossRef] [Google Scholar]
  5. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A metaanalysis of clinically relevant endpoints. Lancet. 1999;354:1940–7. [CrossRef] [PubMed] [Google Scholar]
  6. Augoustides JG, Lin J, Gambone AJ, Cheung AT. Fatal thrombosis in an adult after thoracoabdominal aneurysm repair with aprotinin and deep hypothermic circulatory arrest. Anesthesiology. 2005;103:215–6. [CrossRef] [PubMed] [Google Scholar]
  7. Shore-Lesserson L, Reich DL. A case of severe diffuse venous thromboembolism associated with aprotinin and hypothermic circulatory arrest in a cardiac surgical patient with factor V Leiden. Anesthesiology. 2006;105:219–21. [CrossRef] [PubMed] [Google Scholar]
  8. Dentz ME, Slaughter TF, Mark JB. Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid. Anesthesiology. 1995;82:583–6. [CrossRef] [PubMed] [Google Scholar]
  9. Bennett S. Electrocardiographic ST segment changes associated with aprotinin and reversed with heparin in two patients having coronary artery reoperations. J Cardiothorac Vasc Anesth. 1994;8:202–5. [CrossRef] [Google Scholar]
  10. Alvarez JM, Chandraratna H, Newman MA, Levy JH. Intraoperative coronary thrombosis in association with low-dose aprotinin therapy. J Cardiothorac Vasc Anesth. 1999;13:623–8. [CrossRef] [Google Scholar]
  11. Myles PS, Esmore DE. Intraoperative coronary thrombosis with aprotinin in the pre-bypass period. J Cardiothorac Vasc Anesth. 2007;21:558–60. [CrossRef] [Google Scholar]
  12. Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: Results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg. 1998;116:716–30. [CrossRef] [Google Scholar]
  13. Kluger R, Olive DJ, Stewart AB, Blyth CM. Epsilon-aminocaproic acid in coronary artery bypass graft surgery: Preincision or postheparin? Anesthesiology. 2003;99:1263–9. [CrossRef] [PubMed] [Google Scholar]
  14. Lemmer JHJr, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens. Ann Thorac Surg. 1996;62:1659–68. [CrossRef] [Google Scholar]
  15. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353–65. [CrossRef] [PubMed] [Google Scholar]
  16. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion. 2006;46:327–38. [CrossRef] [PubMed] [Google Scholar]
  17. Hunter D. First, gather the data. N Engl J Med. 2006;354:353–65. [CrossRef] [PubMed] [Google Scholar]
  18. Sedrakyan A, Atkins D, Treasure T. The risk of aprotinin: A conflict of evidence. Lancet. 2006;367:1376–7. [CrossRef] [PubMed] [Google Scholar]
  19. Body SC, Mazer CD. Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery. Anesth Analg. 2006;103:1354–9. [CrossRef] [PubMed] [Google Scholar]
  20. Royston D, Chhatwani A. Safety aspects of aprotinin therapy in cardiac surgery patients. Expert Opin Drug Saf. 2006;5:539–52. [CrossRef] [PubMed] [Google Scholar]
  21. Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32:51–63. [CrossRef] [Google Scholar]
  22. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: Observational studies. Lancet. 2001;357:455–62. [CrossRef] [PubMed] [Google Scholar]
  23. Datta M. You cannot exclude the explanation you have not considered. Lancet. 1993;342:345–7. [CrossRef] [PubMed] [Google Scholar]
  24. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–63. [CrossRef] [PubMed] [Google Scholar]
  25. Connors AFJr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA. 1996;276:889–97. [CrossRef] [PubMed] [Google Scholar]
  26. Wheeler AP, Bernard GR, Thompson BT, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung in-jury. N Engl J Med. 2006;354:2213–24. [CrossRef] [PubMed] [Google Scholar]
  27. Harvey S, Harrison DA, Singer M, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet. 2005;366:472–7. [CrossRef] [PubMed] [Google Scholar]
  28. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analyses using perioperative blood transfusion as the outcome. Anesth Analg. 1997;85:1258–67. [CrossRef] [PubMed] [Google Scholar]
  29. Brown JR, Birkmeyer NJO, O’Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115:2801–13. [CrossRef] [PubMed] [Google Scholar]
  30. Tanaka KA, Sniecinski R. Systemic thromboses after cardiopulmo-nary bypass: Is it thrombin or antithrombin? Anesthesiology. 2006;105:428. [CrossRef] [PubMed] [Google Scholar]
  31. Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg. 1994;8:651–6. [CrossRef] [Google Scholar]
  32. Frumento RJ, O’Malley CMN, Bennett-Guerrero E. Stroke after cardiac surgery: A retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg. 2003;75:479–83. [CrossRef] [Google Scholar]
  33. Poston RS, White C, Gu J, et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg. 2006;81:104–11. [CrossRef] [Google Scholar]
  34. Day JRS, Landis RC, Taylor KM. Aprotinin and the protease-activated receptor 1 thrombin receptor: Antithrombosis, inflamma-tion, and stroke reduction. Semin Cardiothorac Vasc Anesth. 2006;10:132–42. [CrossRef] [PubMed] [Google Scholar]
  35. Karaca P, Konuralp C, Enc Y, et al. Cardioprotective effect of aprotinin on myocardial ischemia/reperfusion injury during cardiopulmonary bypass. Circ J. 2006;70:1432–6. [CrossRef] [PubMed] [Google Scholar]
  36. Risch A, Dorscheid E, Stein G, et al. The effect of aprotinin and tranexamic acid on fibrinolysis and thrombin generation during cardiopulmonary bypass. Anaesthetist. 2000;49:279–85. [CrossRef] [PubMed] [Google Scholar]
  37. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2001;1:CD001886. [Google Scholar]
  38. Mazer D, Fergusson D, Hebert P, et al. Incidence of massive bleeding in a blinded controlled trial of antifibrinolytic drugs. Anesth Analg. 2006;102:SCA95. [Google Scholar]
  39. Myles PS, Smith J, Knight J, Cooper DJ, McNeil J, Silbert B. Aspirin and tranexamic acid for coronary artery surgery: a randomized controlled trial. Accessed June 4, 2007. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.